Potent inhibition of Lp(a) oxidation by icosapent ethyl (IPE) may have contributed to the cardiovascular risk reduction seen in REDUCE-IT in patients with hypertriglyceridaemia, including those with elevated Lp(a) levels.
Olezarsen significantly remodels Lp(a) particles by reducing their TG and cholesterol content, without affecting Lp(a) concentration, according to results from a Phase 2 dose ranging study of the apoC3 inhibitor recently approved in the USA for use in adults with familial chylomicronaemia syndrome (FCS).
